

- COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. *Proc Natl Acad Sci U S A* **98** : 6917-6922, 2001
- 14) Meyer-Lindenberg A, Straub RE, Lipska BK *et al* : Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. *J Clin Invest* **117** : 672-682, 2007
 - 15) Albert KA, Hemmings HC Jr, Adamo AI *et al* : Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. *Arch Gen Psychiatry* **59** : 705-712, 2002
 - 16) Cardno AG, Holmans PA, Rees MI *et al* : A genomewide linkage study of age at onset in schizophrenia. *Am J Med Genet* **105** : 439-445, 2001
 - 17) Gerber DJ, Hall D, Miyakawa T *et al* : Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. *Proc Natl Acad Sci U S A* **100** : 8993-8998, 2003
 - 18) Miyakawa T, Leiter LM, Gerber DJ *et al* : Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. *Proc Natl Acad Sci U S A* **100** : 8987-8992, 2003
 - 19) Zintzaras E : Brain-derived neurotrophic factor gene polymorphisms and schizophrenia : a meta-analysis. *Psychiatr Genet* **17** : 69-75, 2007
 - 20) Kanazawa T, Glatt SJ, Kia-Keating B *et al* : Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. *Psychiatr Genet* **17** : 165-170, 2007
 - 21) Stefansson H, Sigurdsson E, Steinthorsdottir V *et al* : Neuregulin 1 and susceptibility to schizophrenia. *Am J Hum Genet* **71** : 877-892, 2002
 - 22) Gu Z, Jiang Q, Fu AK *et al* : Regulation of NMDA receptors by neuregulin signalling in prefrontal cortex. *J Neurosci* **25** : 4974-4984, 2005
 - 23) Hahn CG, Wang HY, Cho DS *et al* : Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. *Nature Med* **12** : 824-828, 2006
 - 24) Weickert CS, Straub RE, McClintock BW *et al* : Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. *Arch Gen Psychiatry* **61** : 544-555, 2004
 - 25) Straub RE, Jiang Y, MacLean CJ *et al* : Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. *Am J Human Genetics* **71** : 337-348, 2002
 - 26) Feng YQ, Zhou ZY, He X *et al* : Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. *Schizophr Res*, in press
 - 27) Chumakov I, Blumenfeld M, Guerassimenko O *et al* : Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. *Proc Natl Acad Sci U S A* **99** : 13675-13680, 2002
 - 28) Hashimoto A, Nishikawa T, Konno R *et al* : Free d-serine, d-aspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase. *Neurosci Lett* **152** : 33-36, 1993
 - 29) Korostishevsky M, Kaganovich M, Cholostoy A *et al* : Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis. *Biol Psychiatry* **56** : 169-176, 2004
 - 30) Liu H, Heath SC, Sobin C *et al* : Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. *Proc Natl Acad Sci U S A* **99** : 3717-3722, 2002
 - 31) Jacquet H, Raux G, Thibaut F *et al* : PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. *Hum Mol Genet* **11** : 2243-2249, 2002
 - 32) Gogos JA, Santha M, Takacs Z *et al* : The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. *Nat Genet* **21** : 434-439, 1999
 - 33) Mirnics K, Middleton FA, Stanwood GD *et al* : Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. *Mol Psychiatry* **6** : 293-301, 2001
 - 34) Ni YG, Gold SJ, Iredale PA *et al* : Region-specific regulation of RGS4 (Regulator of G-protein-signaling protein type 4) in brain by stress and glucocorticoids : in vivo and in vitro studies. *J Neurosci* **19** : 3674-3680, 1999
 - 35) Blackwood DH, Fordyce A, Walker MT *et al* : Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes : clinical and P300 findings in a family. *Am J Hum Genet* **69** : 428-433, 2001
 - 36) Taya S, Shinoda T, Tsuboi D *et al* : DISC1 regulates the transport of the NUDEL/LIS1/14-3-3 ϵ complex through kinesin-1. *J Neurosci* **27** : 15-26, 2007
 - 37) Hikida T, Jaaro-Peled H, Seshadri S *et al* : Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. *Proc Natl Acad Sci U S A* **104** : 14501-14506, 2007
 - 38) Li W, Zhou Y, Jentsch JD *et al* : Specific developmental

- disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. *Proc Natl Acad Sci U S A* **104** : 18280-18285, 2007
- 39) Leonard S, Gault J, Hopkins J *et al* : Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. *Arch Gen Psychiatry* **59** : 1085-1096, 2002
- 40) Freedman R, Hall M, Adler LE *et al* : Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. *Biol Psychiatry* **38** : 22-33, 1995
- 41) Raedler TJ, Knable MB, Jones DW *et al* : In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. *Am J Psychiatry* **160** : 118-127, 2003
- 42) Emamian ES, Hall D, Birnbaum MJ *et al* : Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. *Nat Genet* **36** : 131-137, 2004
- 43) Nagai T, Takuma K, Kamei H *et al* : Dopamine D1 receptors regulate protein synthesis-dependent long-term recognition memory via extracellular signal-regulated kinase 1/2 in the prefrontal cortex. *Learn Mem* **14** : 117-125, 2007
- 44) Mottola DM, Brewster WK, Cook LL *et al* : Dihydroxidine, a novel full efficacy D1 dopamine receptor agonist. *J Pharmacol Exp Ther* **262** : 383-393, 1992
- 45) George MS, Molnar CE, Grenesko EL *et al* : A single 20 mg dose of dihydroxidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. *Schizophr Res* **93** : 42-50, 2007
- 46) Mu Q, Johnson K, Morgan PS *et al* : A single 20 mg dose of the full D1 dopamine agonist dihydroxidine (DAR-0100) increases prefrontal perfusion in schizophrenia. *Schizophr Res* **94** : 332-341, 2007
- 47) Acker BA, Jacobsen EJ, Rogers BN *et al* : Discovery of N-[(3R, 5R)-1-azabicyclo [3.2.1] oct-3-yl] furo [2,3-c] pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor : In vitro and in vivo activity. *Bioorg Med Chem Lett* **18** : 3611-3615, 2008
- 48) Olincy A, Harris JG, Johnson LL *et al* : Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. *Arch Gen Psychiatry* **63** : 630-638, 2006
- 49) Freedman R, Olincy A, Buchanan RW *et al* : Initial phase 2 trial of a nicotinic agonist in schizophrenia. *Am J Psychiatry* **165** : 1040-1047, 2008
- 50) Heresco-Levy U, Javitt DC : Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia : a retrospective analysis. *Schizophr Res* **66** : 89-96, 2004
- 51) Lane HY, Chang YC, Liu YC *et al* : Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia : a randomized, doubleblind, placebo-controlled study. *Arch Gen Psychiatry* **62** : 1196-1204, 2005
- 52) Patil ST, Zhang L, Martenyi F *et al* : Activation of mGlu2/3 receptors as a new approach to treat schizophrenia : a randomized Phase 2 clinical trial. *Nat Med* **13** : 1102-1107, 2007

代表・分担研究者氏名一覧

「化学物質による神経伝達物質受容体を介した精神毒性発現機序の解明
および行動評価方法の開発に関する研究」

区分	氏名	住所	所属	職名	e-mail
代表	鍋島俊隆	〒468-8503 名古屋市天白区 八事山 150	名城大学大学院 薬学研究科 薬品作用学研究室	教授	tnabeshi@meijo-u.ac.jp
分担	山田清文	〒466-8650 名古屋市昭和区 鶴舞町 65	名古屋大学大学院 医学系研究科 医療薬学・附属病院 薬剤部	教授	kyamada@med.nagoya-u.ac.jp
分担	野田幸裕	〒468-8503 名古屋市天白区 八事山 150	名城大学薬学部 病態解析学	教授	ynoda@ccmfs.meijo-u.ac.jp
分担	永井 拓	〒466-8650 名古屋市昭和区 鶴舞町 65	名古屋大学大学院 医学系研究科 医療薬学・附属病院 薬剤部	准教授	t-nagai@med.nagoya-u.ac.jp
分担	間宮隆吉	〒468-8503 名古屋市天白区 八事山 150	名城大学大学院 薬学研究科 薬品作用学研究室	助教	mamiya@meijo-u.ac.jp

